Bruno Flamion, Professor, Clinical Pharmacology, University of Namur, Belgium and Chair, Scientific Advice Working Party, EMEA

Bruno is an MD who practised internal medicine and nephrology in Belgium. He was a Research Fellow at the NIH (1988-1992) and with the Belgian National Fund for Scientific Research (1992-1996) and later got a PhD in physiological sciences from the University of Brussels. He is now Full Professor of Physiology and Pharmacology at the University of Namur, Belgium, where he heads a molecular physiology lab. He has been involved as a medical expert for the Belgian Federal Agency for Medicines and Health Products (FAMHP) since 1999 and for the EMEA: CHMP, PK group, Pharmacogenomics, and more recently CAT (Committee for Advanced Therapies). His favourite activity is chairing the Scientific Advice Working Party.

Kerstin Franzén, Senior Director, Regulatory Policy & Intelligence, Pfizer, Sweden

Kerstin has a background in Regulatory Affairs covering 29 years. After an academic degree at Uppsala University, M Pharm Sci, she joined the pharmaceutical industry, first for a short period in the marketing area, and then went into the regulatory arena. The first seven years were spent with the Roche affiliate in Sweden, followed by a move to the Swiss headquarters where she stayed for four years, still in Regulatory Affairs. In 1990 she decided to join Kabi Pharmacia and go back to Sweden. This company went through a number of mergers and acquisitions, which eventually led to her current position with Pfizer in Regulatory Policy & Intelligence, an area she has been involved in since 1998.